PPA
PHAT icon

Parametric Portfolio Associates’s Phathom Pharmaceuticals PHAT Stock Holding History

Parametric Portfolio Associates’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,640
Closed -$438K – 3678
2021
Q3 		$438K Buy
+13,640
New +$453K ﹤0.01% 3160

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Parametric Portfolio Associates's PHAT Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Phathom Pharmaceuticals (PHAT) in Q4 2021, closing a stake of 13,640 shares — an estimated $438K sold.

Parametric Portfolio Associates first reported a position in PHAT in Q3 2021 and held it in 1 quarter. The position peaked at $438K in Q3 2021. 83 funds tracked by Wall St. Rank hold PHAT as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Phathom Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 13,640 Phathom Pharmaceuticals shares in Q4 2021, an estimated $438K.
  • Parametric Portfolio Associates first reported a position in Phathom Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Phathom Pharmaceuticals position peaked at $438K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.